CYPHER Stent Continues to Prove Its Worth

JUNE 01, 2007
Susan Farley

A clinical trial comparing stents found that the CYPHER Sirolimus-eluting Coronary Stent had a clinical benefit similar to that of a bare metal stent (BMS), with no differences in incidence of heart attack, death, or blood clots. Data from this new trial support data from a previous trial touting CYPHER?s benefits. In fact, this trial showed that patients in the CYPHER group had significantly lower rates of target vessel failure at the 5-year follow-up than patients in the BMS group (22.5% vs 34.7%). At the long-term follow-up, the CYPHER stent also resulted in lower rates of re-treatment, myocardial infarction, and death, when compared with BMS (9.4% vs 24.2%).

Ms. Farley is a freelance medical writer based in Wakefield, RI.



SHARE THIS SHARE THIS
0

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.